JNJ tecvayli® + talvey® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refrac

JNJ tecvayli® + talvey® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma J&j - tecvayli + talvey reduces risk of progression or death by 89% in relapsed/refractory multiple myeloma - Tecvayli + talvey reduces risk of death by 62% in relapsed/refractory multiple myeloma - Tecvayli + talvey Arm reduces progression or death risk by 89%; talvey + pomalidomide by 73% - Monumental-6 shows significant improvements in progression-free and overall survival versus standard of Care